GE Healthcare (NYSE:GE) announced this week that it won FDA approval for its Invenia Automated Breast Ultrasound system, indicated to help doctors identify cancers in women with dense breast tissue.

The technology may help find 1/3rd more cancers than mammography alone in the estimated 40% of women with dense breasts, and the 1st Invenia ABUS system is slated to go live at a hospital just outside of Washington D.C., according to a GE press release.

"Mammography is still considered the gold standard for breast cancer screening but is less sensitive in women who have dense breast tissue," breast imaging expert Dr. Elise Berman said in prepared remarks on behalf of GE Healthcare. "Supplementing the mammogram with automated breast ultrasound screenings should help us find tumors that cannot be seen on the mammogram and at an earlier stage than would have otherwise been found."

Women with dense breast tissue are at higher risk for developing breast cancer, GE said, and the new Invenia system uses ultrasound to provide 15-minute imaging that provides more thorough images than mammography. The technology is also designed to conform to the body for greater comfort and better imaging.

GE expects to fully roll-out the Invenia system nationwide this year, the company said.

The healthcare titan has been making a lot of moves in women’s health in the past year. GE in July 2013 won European approval for its SenoClaire 3D breast imaging system, which aims to reduce radiation exposure during breast cancer screening. Just weeks later the company filed for FDA approval to include 3D breast imaging, or tomosynthesis, to the Senographe Essential system in the U.S.